Neuroinflammation in Alzheimer's disease: Are NSAIDs and selective COX-2 inhibitors the next line of therapy?

Journal of Alzheimer's Disease

Volumn 21, Issue 4, 2010, Pages 1089-1099

  Trepanier, Catherine H ^a   Milgram, Norton W ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; anti inflammatories; COX 2 inhibitors; neuroinflammation; NSAIDs; TNF

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETANERCEPT; ETORICOXIB; FENOPROFEN; FLURBIPROFEN; HYDROGEN PEROXIDE; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MECLOFENAMIC ACID; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC SULFIDE; TARENFLURBIL; TILMACOXIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VALDECOXIB;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DEMENTIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; HIPPOCAMPUS; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEARNING; LONG TERM EXPOSURE; MAXIMUM PLASMA CONCENTRATION; MAZE TEST; MEDIATOR; MEMORY; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78650452885     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-090667     Document Type: Article

References (75)

1. McGeer PL and McGeer EG (1999) Inflammation of the brain in Alzheimer's disease: implications for therapy. J Leukoc Biol 65, 409-415.
2. Terai K, McGeer EG, McGeer PL (1997) Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 769, 385-390.
3. Shen Y, Li R, McGeer EG, McGeer PL (1997) Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 769, 391-395.
4. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358, 461-467.
5. Rozemuller JM, Stam FC and Eikelenboom P (1990) Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex in patients with Alzheimer's disease. Neurosci Lett 119, 75-78.
6. Banati RB, Myers R, Kreutzberg GW (1997) PK ('peripheral benzodiazepine')-binding sites in the CNS indicate early and discrete brain lesions: Microautoradiographic detection of [3H]PK11195 binding to activated microglia. JNeurocytol 26, 77-82.
7. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 94, 1500-1505.
8. Bellinger FP, Madamba SG, Campbell IL, Siggins GR (1995) Reduced long-term potentiation in the dentate gyrus of trans-genic mice with cerebral overexpression ofinterleukin-6. Neu-rosci Lett 198, 95-98.
9. Hauss-Wegrzyniak B, Dobrzanski P, Snoehr JD, Wenk GL. Chronic neuroinflammation in rats reproduce components of the neurobiology of Alzheimer's disease. Brain Res 780, 294-303.
10. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
11. McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22, 799-809.
12. Weiner HL, Frenkel D (2006) Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6, 404-416.
13. Eikelenboom P, Crosswell A, van Engen C, Limper M, Hooze-mans JJM, Veerhuis R, van Gool WA and Rozemuller JM (2008) Chapter 12: Neuroinflammation in Early Stages of Alzheimer's Disease and Parkinson's Disease. In Advances in Alzheimer's and Parkinson's Disease, Fisher A, Memo M, Stocchi F, Hanin I, eds. Springer US, pp. 113-121.
14. Radi ZA (2009) Pathophysiology of cyclooxygenase inhibition in animal models. Toxicol Pathol 37, 34-46.
15. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L and Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91, 12013-12017.
16. Hoozemans JJ, Veerhuis R, Janssen I, van Elk EJ, Rozemuller AJ, Eikelenboom P (2002a) The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res 951, 218-226.
17. Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87, 319-324.
18. Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P, Arendt T (2002) Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol 61,678-688.
19. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hof-man A (1995) Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45, 1441-1445.
20. In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345, 1515-1521.
21. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
22. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Bre-itner JC (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 59, 880-886.
23. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156, 445-453.
24. Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, Stone SV (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54, 2066-2071.
25. Beard CM, Waring SC, O'Brien PC, Kurland LT, Kok-men E (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Mi-neesota, 1980 through 1984. Mayo Clin Proc 73, 951-955.
26. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44, 227-232.
27. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM (1995) Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16, 523-530.
28. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, Brooks WS, Halliday GM (2000) Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57, 1586-1591.
29. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer's disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28, 639-647.
30. Szekely CA, Green RC, Breitner JC, 0stbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP (2008) No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70, 2291-2298.
31. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Butler T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic A/42 independently of cyclooxygenase activity. Nature 414, 212-216.
32. Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, Evans DA, Bennett DA (2008) Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70, 2219-2225.
33. Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, Larson EB (2009) Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899-1905.
34. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLen-don DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE (2003) NSAIDs and enantiomers of flurbiprofen target 7-secretase and lower A/42 in vivo. J Clin Invest 112, 440-449.
35. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
36. Hsiao K., Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S,Yang F, Cole G, (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
37. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. JNeurosci 21, 372-381.
38. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Hsiao Ashe K, Frautschy SA and Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20, 57095714.
39. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH and Golde TE (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A/42 production. Nat Med 11, 545-550.
40. Van Dam D, Coen K, De Deyn PP (2010) Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. JPsychopharmacol 24, 383-388.
41. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur JNeurosci 17, 388-396.
42. Sturchler-Pierrat C, Abramowki D, Duke M, Wiederhold KH, Mistl C, Rotacher S, Ledermann B, Biirki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein trans-genic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94, 13287-13292.
43. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008) Ibuprofen reduces A/3, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207, 225-236.
44. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE and Nicolle MM (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 8, 54-66.
45. Rall JM, Mach SA, Dash PK (2003) Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res 968, 273-276.
46. Sharifzadeh M, Naghdi N, Khosrovani S, Ostad SN, Shar-ifzadeh K and Roghani A (2005) Post-training intrahippocam-pal infusion of the COX-2 inhibitor celecoxib impaired spatial memory retention in rats. Eur J Pharmacol 511, 159-166. (Pubitemid 40417722)
47. Sharifzadeh M, Tavasoli M, Soodi M, Mohammadi-Eraghi S, Ghahremani MH and Roghani A (2006) A time course analysis of cyclooxygenase-2 suggests a role in spatial memory retrieval in rats. Neurosci Res 54, 171-179.
48. Zhao X, Rebeck GW, Hoe HS, Andrews PM (2008) Tarenflur-bil protection from cytotoxicity is associated with an upregu-lation of neurotrophins. J Alzheimers Dis 15, 397-407.
49. Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM (2005) Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology 30, 1111-1120.
50. Sanz-Blasco S, Valero RA, Rodriguez-Crespo I, Villalobos C, Nmiez L (2008) Mitochondrial Ca2+ overload underlies A/oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE 3, e2718.
51. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611.
52. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N (1999) A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53, 197-201.
53. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression -A randomized controlled trial. JAMA 289, 2819-2826.
54. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66-71.
55. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharma- cology 30, 1204-1215.
56. Soininen H, West C, Robbins J, Niculescu L (2007) Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 23, 8-21.
57. ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800-1808.
58. ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JCS, Evans D, Green R, Mullan M (2008) Cognitive function overtime in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT). Arch Neurol 65, 896-905.
59. ADAPT Research Group (2006) Cardiovascular and cere-brovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1, e33.
60. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 7, 483-493.
61. Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng WK, Fong C, Lee JS, Chan MH, Szeto SS, Lui VW, Tsoh J, Kwok TC, Chan IH, Lam CW (2007) Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 56, 509-514.
62. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Ca-purso A, Panza F (2006) Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 364, 91-112. (Pubitemid 43120631)
63. Perry RT, Collins JS, Wiener H, Acton R, Go RC (2001) The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 22, 873-883.
64. Pickering M, Cumiskey D, O'Connor JJ (2005) Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 90, 663-670.
65. Tweedie D, Sambamurtri K, Greig NH (2007) TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: New drug candidates and targets. Curr Alzheimer Res 4, 375-378.
66. Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M (2007) Serum TNF-alpha levels are increased and correlate negatively with free IGF-1 in Alzheimer disease. Neurobiol Aging 28, 533-536.
67. Medeiros R, Prediger RD, assos GF, Pandolfo P, Duarte FS, Franco JL, Dafre AL, Di Giunta G, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB (2007) Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: Relevance for the behavioural and synaptic deficits induced by amyloi-beta protein. J Neurosci 27, 5394-5404.
68. Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH, Edwards KL, Schellenberg GD, Hansen JA, Kukull WA, Jin LW (2006) Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol 63, 1165-1169.
69. Tobinick E, Gross H, Weinberger A, Cohen H (2006) TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 8, 25.
70. Tarkowki E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K (2003) Cerebral pattern of pro-and anti-inflammatory cytokines in dementias. Brain Res Bull 61, 255260.
71. Tobinick EL, Gross H (2008) Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurology 8, 27-36.
72. Tobinick EL, Gross H (2008) Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 5, 2.
73. Amgen Statement on Alzheimer's Case Study: . amgen.com/media/rapid- cognitive-improvement.html. Published online Jan. 10, 2008, Accessed on March 15, 2009.
74. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432.
75. Studzinski CM, Araujo JA, Milgram NW (2005) The canine model ofhuman cognitive aging and dementia: Pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuropsychopharmacol Biol Psychiatry 29, 489-498.